 |
|
|
| |
High Efficacy is Accompanied with Substantial Gains in Patient Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C Treated with Sofosbuvir, Velpatasvir with or without Voxilaprevir: The Data from POLARIS-1, -2, -3 and -4
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Zobair M. Younossi, Maria Stepanova, Ira Jacobson, Stefan Zeuzem, Marc Bourliere, Graham Foster, Stuart Roberts, Tarik Asselah, Alexander Thompson, Ed Gane, Bernard Willems, Eric Lawitz, Stuart Gordon,
Michael Mann, K. Rajender Reddy, Curtis Cooper, Steven Flamm, Kris Kowdley, Sharon Hunt
1.Center for Liver Diseases, Department of Medicine, Falls Church, VA, United States.
2.Center for Outcomes Research in Liver Diseases (COR-LD), Washington, DC, United States.
3.Mount Sinai Beth Israel Hospital, New York City, NY, United States.
4.Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany.
5.Hospital Saint Joseph, Marseille, France.
6.London Bridge Hospital, London, United Kingdom.
7.Alfred Hospital, Victoria, Australia.
8.Hopital Beaujon, Paris, France.
9.St. Vincent's Hospital, Melbourne, Australia.
10.University Auckland, Auckland, New Zealand.
11.University of Montreal, Montreal, Canada.
12.Texas Liver Institute, San Antonio, TX, United States.
13.Henry Ford Health System, Detroit, MI, United States.
14.Hannover Medical School, Meintz, Germany.
15.University of Pennsylvania, Philadelphia, PA, United States.
16.Ottawa Hospital Research Institute, Ottawa.
17.Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
18.Swedish Medical Center, Seattle, WA, United States.
|
| |
|
|
|
|
|
